TY - JOUR
T1 - Genomic Classification of Cutaneous Melanoma
AU - The Cancer Genome Atlas Network
AU - Akbani, Rehan
AU - Akdemir, Kadir C.
AU - Aksoy, B. Arman
AU - Albert, Monique
AU - Ally, Adrian
AU - Amin, Samirkumar B.
AU - Arachchi, Harindra
AU - Arora, Arshi
AU - Auman, J. Todd
AU - Ayala, Brenda
AU - Baboud, Julien
AU - Balasundaram, Miruna
AU - Balu, Saianand
AU - Barnabas, Nandita
AU - Bartlett, John
AU - Bartlett, Pam
AU - Bastian, Boris C.
AU - Baylin, Stephen B.
AU - Behera, Madhusmita
AU - Belyaev, Dmitry
AU - Benz, Christopher
AU - Bernard, Brady
AU - Beroukhim, Rameen
AU - Bir, Natalie
AU - Black, Aaron D.
AU - Bodenheimer, Tom
AU - Boice, Lori
AU - Boland, Genevieve M.
AU - Bono, Riccardo
AU - Bootwalla, Moiz S.
AU - Bosenberg, Marcus
AU - Bowen, Jay
AU - Bowlby, Reanne
AU - Bristow, Christopher A.
AU - Brockway-Lunardi, Laura
AU - Brooks, Denise
AU - Brzezinski, Jakub
AU - Bshara, Wiam
AU - Buda, Elizabeth
AU - Burns, William R.
AU - Butterfield, Yaron S.N.
AU - Button, Michael
AU - Calderone, Tiffany
AU - Cappellini, Giancarlo Antonini
AU - Carter, Candace
AU - Carter, Scott L.
AU - Cherney, Lynn
AU - Cherniack, Andrew D.
AU - Chevalier, Aaron
AU - Walter, Vonn
N1 - Funding Information:
We thank all patients and families who contributed to this study. We are grateful to Chris Gunter for manuscript editing and Ina Felau and Margi Sheth for project management. This article is dedicated to the memory of Donald L. Morton, M.D., a pioneer in melanoma oncology, who passed away on January 10, 2014. This study was supported by NIH grants: U54 HG003273, U54 HG003067, U54 HG003079, U24 CA143799, U24 CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848, U24 CA143858, U24 CA143866, U24 CA143867, U24 CA143882, U24 CA143883, U24 CA144025, and P30 CA016672.
Funding Information:
A.D.C. and M.M. receive research funding from Bayer AG. M.M. is a founder of, equity holder in, and consultant for Foundation Medicine, a next-generation sequencing-based cancer diagnostics company. L.A.G. received a commercial research grant from Novartis and is a consultant/advisory board member for Novartis, Foundation Medicine, and Boehringer Ingelheim. L.A.G. also has equity interest in Foundation Medicine. D.J.W. is a consultant for Zymo Research Corporation, which distributes commercially available products for DNA methylation-based experiments. Zymo Research neither supported this work nor has an interest in the outcome of this research. O.P and O.V. are co-founders and shareholders of Cureline, Inc., which received a contract payment from the NIH for this work. J.E.G. is an advisory board member for Merck.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/6/20
Y1 - 2015/6/20
N2 - Summary We describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protein-based analysis of 333 primary and/or metastatic melanomas from 331 patients. We establish a framework for genomic classification into one of four subtypes based on the pattern of the most prevalent significantly mutated genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type). Integrative analysis reveals enrichment of KIT mutations and focal amplifications and complex structural rearrangements as a feature of the Triple-WT subtype. We found no significant outcome correlation with genomic classification, but samples assigned a transcriptomic subclass enriched for immune gene expression associated with lymphocyte infiltrate on pathology review and high LCK protein expression, a T cell marker, were associated with improved patient survival. This clinicopathological and multi-dimensional analysis suggests that the prognosis of melanoma patients with regional metastases is influenced by tumor stroma immunobiology, offering insights to further personalize therapeutic decision-making.
AB - Summary We describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protein-based analysis of 333 primary and/or metastatic melanomas from 331 patients. We establish a framework for genomic classification into one of four subtypes based on the pattern of the most prevalent significantly mutated genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type). Integrative analysis reveals enrichment of KIT mutations and focal amplifications and complex structural rearrangements as a feature of the Triple-WT subtype. We found no significant outcome correlation with genomic classification, but samples assigned a transcriptomic subclass enriched for immune gene expression associated with lymphocyte infiltrate on pathology review and high LCK protein expression, a T cell marker, were associated with improved patient survival. This clinicopathological and multi-dimensional analysis suggests that the prognosis of melanoma patients with regional metastases is influenced by tumor stroma immunobiology, offering insights to further personalize therapeutic decision-making.
UR - http://www.scopus.com/inward/record.url?scp=84935009372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84935009372&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2015.05.044
DO - 10.1016/j.cell.2015.05.044
M3 - Article
C2 - 26091043
AN - SCOPUS:84935009372
SN - 0092-8674
VL - 161
SP - 1681
EP - 1696
JO - Cell
JF - Cell
IS - 7
ER -